Growth and puberty and its management in thalassaemia
- PMID: 12373018
- DOI: 10.1159/000064766
Growth and puberty and its management in thalassaemia
Abstract
The purpose of this review is to report the personal experience on growth and pubertal development in a large number of thalassaemic and ex-thalassaemic patients followed at the Pediatric and Adolescent Unit of Ferrara. Secondary amenorrhoea (SA), hypogonadism and short stature are the commonest endocrine and auxological complications. The anterior pituitary gland is particularly sensitive to free radical oxidative stresses and exposure to this. Magnetic resonance imaging (MRI) shows that even a modest amount of iron deposition within the anterior pituitary can interfere with its function. Other possible cause of hypogonadism in beta-thalassaemia major include liver disorders, chronic hypoxia, diabetes mellitus and zinc deficiency. The treatment of pubertal disorders consists of hormone replacement therapy with sex steroids. Successful induction of spermatogenesis and ovulation has been reported after hormonal stimulation with gonadotrophins. Height above the 10th centile was achieved in 50% of males and 64% of females. Eight prepubertal thalassaemic patients, 6 males and 2 females, ranging in age from 8.6 to 11.7 years, were treated with GH. After the first 12 months of GH treatment a significant increase of growth velocity was observed in 6 patients who doubled growth velocity before basal value (4 cm or more above the basal value), 2 patients had a partial response (2-4 cm above the basal value). In the following 3 years all thalassaemic patients had a partial response to the treatment with GH. These data indicate that despite somewhat reduced sensitivity to GH, compared to GH deficiency children, there is evidence indicating that thalassaemic patients may benefit from GH treatment. Sixty-eight thalassaemic patients (30 males and 38 females) who had successfully undergone bone marrow transplantation (BMT) during childhood were studied. Following BMT growth rate decelerated when compared to Tanner and Whitehouse standards. Twenty-nine ex-thalassaemics reached final height. The patterns of growth during puberty was variable in ex-thalassaemic males, while in all but 3 ex-thalassaemic females we observed an improvement in the percentile of standing height. A gonadal dysfunction was found in 68% of ex-thalassaemic patients. Since the quality of life of these patients is an important aim, it is vital to monitor carefully the growth and pubertal development in order to detect abnormalities and to initiate appropriate and early treatment.
Copyright 2002 S. Karger AG, Basel
Similar articles
-
Growth, puberty and endocrine function in beta-thalassaemia major.J Pediatr Endocrinol Metab. 1997 Mar-Apr;10(2):175-84. doi: 10.1515/jpem.1997.10.2.175. J Pediatr Endocrinol Metab. 1997. PMID: 9364350 Review.
-
Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion.Eur J Pediatr. 1997 Oct;156(10):777-83. doi: 10.1007/s004310050711. Eur J Pediatr. 1997. PMID: 9365067
-
Growth and management of short stature in thalassaemia major.J Pediatr Endocrinol Metab. 1998;11 Suppl 3:835-44. J Pediatr Endocrinol Metab. 1998. PMID: 10091154
-
Pubertal development in thalassaemic patients after allogenic bone marrow transplantation.Eur J Pediatr. 1993 Dec;152(12):993-7. doi: 10.1007/BF01957223. Eur J Pediatr. 1993. PMID: 8131819
-
Growth and puberty in thalassemia major.J Pediatr Endocrinol Metab. 2003 Mar;16 Suppl 2:259-66. J Pediatr Endocrinol Metab. 2003. PMID: 12729401 Review.
Cited by
-
Bisphosphonate therapy in pediatric patients.J Diabetes Metab Disord. 2014 Dec 17;13(1):109. doi: 10.1186/s40200-014-0109-y. eCollection 2014. J Diabetes Metab Disord. 2014. PMID: 25551100 Free PMC article. Review.
-
Fracture prevalence and relationship to endocrinopathy in iron overloaded patients with sickle cell disease and thalassemia.Bone. 2008 Jul;43(1):162-168. doi: 10.1016/j.bone.2008.03.003. Epub 2008 Mar 15. Bone. 2008. PMID: 18430624 Free PMC article.
-
A Systematic Review and Meta-Analysis of Stature Growth Complications in β-thalassemia Major Patients.Ann Glob Health. 2021 Jun 8;87(1):48. doi: 10.5334/aogh.3184. Ann Glob Health. 2021. PMID: 34164261 Free PMC article.
-
Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone.J Endocrinol Invest. 2005 Apr;28(4):363-6. doi: 10.1007/BF03347204. J Endocrinol Invest. 2005. PMID: 15966511 Clinical Trial.
-
Growth hormone therapy for people with thalassaemia.Cochrane Database Syst Rev. 2020 May 28;5(5):CD012284. doi: 10.1002/14651858.CD012284.pub3. Cochrane Database Syst Rev. 2020. PMID: 32463488 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical